171 related articles for article (PubMed ID: 15804320)
1. Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the Functional Assessment of Cancer Therapy-Biologic Response Modifiers (FACT-BRM) instrument.
Yost KJ; Sorensen MV; Hahn EA; Glendenning GA; Gnanasakthy A; Cella D
Value Health; 2005; 8(2):117-27. PubMed ID: 15804320
[TBL] [Abstract][Full Text] [Related]
2. Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire.
Askew RL; Xing Y; Palmer JL; Cella D; Moye LA; Cormier JN
Value Health; 2009; 12(8):1144-50. PubMed ID: 19558579
[TBL] [Abstract][Full Text] [Related]
3. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers.
Bacik J; Mazumdar M; Murphy BA; Fairclough DL; Eremenco S; Mariani T; Motzer RJ; Cella D
Qual Life Res; 2004 Feb; 13(1):137-54. PubMed ID: 15058795
[TBL] [Abstract][Full Text] [Related]
4. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches.
Yost KJ; Cella D; Chawla A; Holmgren E; Eton DT; Ayanian JZ; West DW
J Clin Epidemiol; 2005 Dec; 58(12):1241-51. PubMed ID: 16291468
[TBL] [Abstract][Full Text] [Related]
5. Quality of life on imatinib.
Hahn EA; Glendenning GA
Semin Hematol; 2003 Apr; 40(2 Suppl 2):31-6. PubMed ID: 12783373
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
Hahn EA; Glendenning GA; Sorensen MV; Hudgens SA; Druker BJ; Guilhot F; Larson RA; O'Brien SG; Dobrez DG; Hensley ML; Cella D;
J Clin Oncol; 2003 Jun; 21(11):2138-46. PubMed ID: 12775739
[TBL] [Abstract][Full Text] [Related]
7. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia.
Aziz Z; Iqbal J; Aaqib M; Akram M; Saeed A
Leuk Lymphoma; 2011 Jun; 52(6):1017-23. PubMed ID: 21534871
[TBL] [Abstract][Full Text] [Related]
8. A brief symptom index for advanced renal cell carcinoma.
Eton DT; Cella D; Bacik J; Motzer RJ
Health Qual Life Outcomes; 2006 Sep; 4():68. PubMed ID: 17002808
[TBL] [Abstract][Full Text] [Related]
9. Assessing responsiveness of generic and specific health related quality of life measures in heart failure.
Eurich DT; Johnson JA; Reid KJ; Spertus JA
Health Qual Life Outcomes; 2006 Nov; 4():89. PubMed ID: 17125512
[TBL] [Abstract][Full Text] [Related]
10. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer.
Cella D; Nichol MB; Eton D; Nelson JB; Mulani P
Value Health; 2009; 12(1):124-9. PubMed ID: 18647260
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Functional Assessment of Cancer Therapy-General (FACT-G) Spanish Version 4 in South America: classic psychometric and item response theory analyses.
Dapueto JJ; Francolino C; Servente L; Chang CH; Gotta I; Levin R; Abreu Mdel C
Health Qual Life Outcomes; 2003 Aug; 1():32. PubMed ID: 12969512
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
13. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.
Eton DT; Cella D; Yost KJ; Yount SE; Peterman AH; Neuberg DS; Sledge GW; Wood WC
J Clin Epidemiol; 2004 Sep; 57(9):898-910. PubMed ID: 15504633
[TBL] [Abstract][Full Text] [Related]
14. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.
Cella D; Eton DT; Fairclough DL; Bonomi P; Heyes AE; Silberman C; Wolf MK; Johnson DH
J Clin Epidemiol; 2002 Mar; 55(3):285-95. PubMed ID: 11864800
[TBL] [Abstract][Full Text] [Related]
15. Preliminary validation of an optimally weighted patient-based utility index by application to randomized trials in breast cancer.
Grimison PS; Simes RJ; Hudson HM; Stockler MR
Value Health; 2009 Sep; 12(6):967-76. PubMed ID: 19490566
[TBL] [Abstract][Full Text] [Related]
16. Reproducibility and responsiveness of the Symptom Severity Scale and the hand and finger function subscale of the Dutch arthritis impact measurement scales (Dutch-AIMS2-HFF) in primary care patients with wrist or hand problems.
Spies-Dorgelo MN; Terwee CB; Stalman WA; van der Windt DA
Health Qual Life Outcomes; 2006 Nov; 4():87. PubMed ID: 17096845
[TBL] [Abstract][Full Text] [Related]
17. Single- vs. multiple-item instruments in the assessment of quality of life in patients with advanced cancer.
Bush SH; Parsons HA; Palmer JL; Li Z; Chacko R; Bruera E
J Pain Symptom Manage; 2010 Mar; 39(3):564-71. PubMed ID: 20303030
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors.
Prinsen CA; Lindeboom R; Sprangers MA; Legierse CM; de Korte J
J Invest Dermatol; 2010 May; 130(5):1318-22. PubMed ID: 20032989
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19.
Submacular Surgery Trials Research Group
Ophthalmic Epidemiol; 2007; 14(4):205-15. PubMed ID: 17896299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
